Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Primary Myelofibrosis 2Myeloproliferative Disorders 2Thrombocytosis 1Polycythemia Vera 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1B-Cell Malignancies 1

Interventions

Ipilimumab 98pembrolizumab 84Nivolumab 82aldesleukin 51Cyclophosphamide 49Interleukin-2 38fludarabine phosphate 31Vemurafenib 31Dacarbazine 31dabrafenib 29trametinib 28Temozolomide 26fludarabine 25CTLA-4 Antigen 18Bevacizumab 18Radiosurgery 15Paclitaxel 15Carboplatin 14encorafenib 13binimetinib 13Introns 13talimogene laherparepvec 12Radiotherapy 12Interferon alpha-2 12spartalizumab 11cobimetinib 10atezolizumab 10sargramostim 9peginterferon alfa-2b 9montanide ISA 51 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Melanoma × INCB039110 × Clear all
NCT03272464 2023-09-22

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Massachusetts General Hospital

Phase 1 Terminated
1 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡